NCT02551718
|
Phase I |
Bosutinib
Irinotecan
romidepsin
Busulfan
Melphalan
Nilotinib
Crizotinib
Cytarabine
Mitoxantrone
Dasatinib
Pazopanib
Paclitaxel
Clofarabine
Hydroxyurea
Tretinoin
Carfilzomib
Nelarabine
Bexarotene
Pentostatin
Everolimus
Cabozantinib
Mercaptopurine
Methotrexate
Cladribine
Thioguanine
Daunorubicin
Ponatinib
Etoposide
Afatinib
Gefitinib
Gemcitabine
Regorafenib
Arsenic trioxide
Trametinib
Imatinib
Erlotinib
Dabrafenib
Decitabine
Axitinib
Azacitidine
Ruxolitinib
Fludarabine
Lapatinib
Ceritinib
Sirolimus
Sorafenib
Lomustine
Sunitinib
Cabazitaxel
Temsirolimus
Topotecan
Bortezomib
Pralatrexate
|
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
NCT02581943
|
Phase II |
Paclitaxel
Pembrolizumab
Carboplatin
|
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer |
Recruiting |
NCT02514551
|
Phase II |
Paclitaxel
Ramucirumab
|
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer |
Active, not recruiting |
NCT00828009
|
Phase II |
Cyclophosphamide
Bevacizumab
Paclitaxel
Emepepimut-S
Carboplatin
|
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
NCT01572727
|
Phase II |
Buparlisib + Paclitaxel
Paclitaxel
|
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation |
Completed |
NCT02788201
|
Phase II |
Erlotinib
Thiotepa
Imatinib
Dacarbazine
Arsenic trioxide
Idarubicin
Mitomycin C
Thioguanine
Mercaptopurine
Methotrexate
Cladribine
epirubicin
Gemcitabine
Doxorubicin
Bleomycin
Etoposide
Gefitinib
Daunorubicin
Lomustine
Sorafenib
Sunitinib
Ifosfamide
Asparaginase
Ixabepilone
Abiraterone
Azacitidine
Ruxolitinib
Decitabine
Axitinib
Estramustine
Floxuridine
Lapatinib
Carmustine
Fludarabine
Nilotinib
Cisplatin
Vismodegib
Vandetanib
Melphalan
Busulfan
Carboplatin
Toremifine
Crizotinib
Dactinomycin
Temsirolimus
Vorinostat
romidepsin
Fluorouracil
Irinotecan
Bortezomib
Tamoxifen
Topotecan
Chlorambucil
Pentostatin
Eribulin
Carfilzomib
Vemurafenib
Hydroxyurea
Exemestane
Vincristine
Dasatinib
Mitoxantrone
Vinblastine
Cytarabine
Tretinoin
Clofarabine
Teniposide
Docetaxel
Pazopanib
Oxaliplatin
Streptozocin
Paclitaxel
Bendamustine
Mechlorethamine
Mitotane
|
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Recruiting |
NCT01249443
|
Phase I |
Carboplatin
Vorinostat
Paclitaxel
|
Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection |
Terminated |
NCT02312245
|
Phase II |
Topotecan
Doxorubicin
Paclitaxel
Gemcitabine
|
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
NCT02440425
|
Phase II |
Paclitaxel
Pembrolizumab
|
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer |
Active, not recruiting |
NCT01407562
|
Phase I |
Carboplatin
Paclitaxel
Pazopanib
|
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors |
Active, not recruiting |
NCT02134067
|
Phase I |
TAS-119
Paclitaxel
|
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors |
Recruiting |
NCT01892046
|
Phase I |
Carboplatin
SNX-5422
Paclitaxel
|
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors |
Completed |
NCT02483247
|
Phase Ib/II |
Paclitaxel
Doxorubicin
Capecitabine
Nivolumab
Sunitinib
Pembrolizumab
BBI503
|
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer |
Active, not recruiting |
NCT01572038
|
Phase III |
Pertuzumab + Trastuzumab
nab-paclitaxel
Docetaxel
Paclitaxel
|
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) |
Active, not recruiting |
NCT02297230
|
Phase Ib/II |
Capecitabine
Paclitaxel
Trastuzumab + Paclitaxel
|
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics |
Terminated |
NCT01501487
|
FDA approved |
Docetaxel + Doxorubicin + Cyclophosphamide
Fluorouracil + Epirubicin + Cyclophosphamide
Paclitaxel
Pegfilgrastim
Docetaxel + Cyclophosphamide
Doxorubicin + Cyclophosphamide
Trastuzumab + Docetaxel + Carboplatin
Pertuzumab + Trastuzumab + Docetaxel
|
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I |
Completed |
NCT01248949
|
Phase I |
Bevacizumab
MEDI3617
Gemcitabine
Carboplatin
Paclitaxel
|
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors |
Completed |
NCT02403895
|
Phase II |
Vistusertib
Paclitaxel
|
AZD2014 and Weekly Paclitaxel in Squamous NSCLC |
Terminated |
NCT01042522
|
Phase II |
Carboplatin
Cisplatin
Paclitaxel
Etoposide
Bleomycin
|
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors |
Recruiting |
NCT01952249
|
Phase Ib/II |
Demcizumab
Paclitaxel
|
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian |
Terminated |
NCT01015222
|
Phase I |
methylnaltrexone
Dasatinib
Paclitaxel
Bevacizumab
|
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies |
Active, not recruiting |
NCT01366144
|
Phase I |
Paclitaxel
Veliparib
Carboplatin
|
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction |
Suspended |
NCT01962948
|
Phase II |
Paclitaxel
Ganetespib
|
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT02301988
|
Phase II |
Paclitaxel
Ipatasertib
|
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer |
Completed |
NCT03517449
|
Phase III |
Lenvatinib + Pembrolizumab
Paclitaxel
Doxorubicin
|
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) |
Recruiting |
NCT02322281
|
Phase III |
Pemetrexed
Gemcitabine
Paclitaxel
Docetaxel
Rociletinib
|
TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy |
Terminated |
NCT02187991
|
Phase II |
Alisertib
Paclitaxel
|
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer |
Active, not recruiting |
NCT02073487
|
Phase II |
Paclitaxel
Trastuzumab emtansine + Lapatinib
Trastuzumab + Lapatinib
nab-paclitaxel
|
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel |
Active, not recruiting |
NCT03181100
|
Phase II |
nab-paclitaxel
Paclitaxel
Atezolizumab + Cobimetinib
Atezolizumab + Bevacizumab
Atezolizumab + nab-paclitaxel
Atezolizumab + Vemurafenib + Cobimetinib
Atezolizumab + Paclitaxel
|
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas |
Recruiting |
NCT02474173
|
Phase I |
Paclitaxel
AT13387
|
HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer |
Recruiting |
NCT02819518
|
Phase III |
Paclitaxel
Pembrolizumab
nab-paclitaxel
Carboplatin + Gemcitabine
|
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) |
Active, not recruiting |
NCT02620865
|
Phase Ib/II |
Paclitaxel
Aldesleukin
Oxaliplatin
Sargramostim
Gemcitabine
Fluorouracil + Leucovorin
|
Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Active, not recruiting |
NCT02419417
|
Phase Ib/II |
BMS986158
Paclitaxel
|
Study of BMS-986158 in Subjects With Select Advanced Solid Tumors |
Recruiting |
NCT02122770
|
Phase I |
Paclitaxel
Docetaxel
Itraconazole
Carboplatin
MLN4924
Fluconazole
|
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors |
Completed |
NCT03693612
|
Phase Ib/II |
GSK3359609 + Tremelimumab
Paclitaxel
Docetaxel
Cetuximab
|
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors |
Recruiting |
NCT01803282
|
Phase I |
GS-5745
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Carboplatin + Pemetrexed
FOLFIRI
Nab-paclitaxel + Gemcitabine
Paclitaxel + Carboplatin
Paclitaxel
Bevacizumab
|
Safety and Tolerability Study in Solid Tumors |
Active, not recruiting |
NCT01281176
|
|
Paclitaxel
Vorinostat
Carboplatin
|
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors |
Active, not recruiting |
NCT02178956
|
Phase III |
Napabucasin
Paclitaxel
|
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer |
Active, not recruiting |
NCT01320592
|
Phase I |
Palbociclib
Paclitaxel
|
PD0332991/Paclitaxel in Advanced Breast Cancer |
Active, not recruiting |
NCT02312804
|
Phase I |
Paclitaxel
Carboplatin
BGJ398
|
Ph Ib/BGJ398/Cervix and Other Solid Tumors |
Withdrawn |
NCT01796197
|
Phase II |
Doxorubicin + Cyclophosphamide
Pertuzumab + Trastuzumab
Paclitaxel
|
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa |
Active, not recruiting |
NCT02341456
|
Phase I |
Adavosertib
Carboplatin
Paclitaxel
|
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours |
Completed |
NCT02009449
|
Phase I |
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Pembrolizumab
Carboplatin
Gemcitabine
Docetaxel
Pazopanib
Capecitabine
Paclitaxel
Cisplatin
Pegilodecakin
nab-paclitaxel
|
A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors |
Active, not recruiting |
NCT02230319
|
Phase II |
Paclitaxel
|
Prevention of Paclitaxel Neuropathy With Cryotherapy |
Unknown status |
NCT02041533
|
Phase III |
Nivolumab
Paclitaxel
Cisplatin
Pemetrexed
Carboplatin
Gemcitabine
|
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) |
Active, not recruiting |
NCT02581982
|
Phase II |
Pembrolizumab
Paclitaxel
|
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer |
Recruiting |
NCT01281150
|
Phase I |
Veliparib
Paclitaxel
Carboplatin
|
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
Completed |
NCT03337724
|
Phase II |
Ipatasertib + Paclitaxel
Paclitaxel
|
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) |
Recruiting |
NCT02574078
|
Phase I |
nab-paclitaxel
Crizotinib
Bevacizumab + Pemetrexed
Paclitaxel
Docetaxel
Nivolumab
Pemetrexed
Gemcitabine
Erlotinib
Carboplatin
|
A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370) |
Active, not recruiting |
NCT01779050
|
Phase II |
Trastuzumab
Docetaxel
Epirubicin + Cyclophosphamide
Paclitaxel
Fluorouracil + Epirubicin + Cyclophosphamide
Docetaxel + Carboplatin
Docetaxel + Cyclophosphamide
|
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells |
Active, not recruiting |
NCT02142738
|
Phase III |
Cisplatin
Paclitaxel
Carboplatin
Gemcitabine
Pembrolizumab
Pemetrexed
|
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) |
Active, not recruiting |
NCT02826161
|
Phase III |
Napabucasin + Paclitaxel
Paclitaxel
|
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) |
Terminated |
NCT02229149
|
Phase II |
Paclitaxel
Docetaxel
Pertuzumab + Trastuzumab
nab-paclitaxel
Vinorelbine
Trastuzumab
Capecitabine
|
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer |
Active, not recruiting |
NCT02625623
|
Phase III |
Avelumab
Paclitaxel
Irinotecan
|
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) |
Active, not recruiting |
NCT01656538
|
Phase II |
Reolysin
Paclitaxel
|
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer |
Completed |
NCT01641939
|
Phase III |
Docetaxel
Paclitaxel
trastuzumab emtansine
|
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer |
Terminated |
NCT02038647
|
Phase II |
Paclitaxel
Alisertib
|
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) |
Completed |
NCT02855944
|
Phase III |
Cisplatin
Rucaparib
Carboplatin
Gemcitabine
Paclitaxel
|
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
Recruiting |
NCT02599324
|
Phase Ib/II |
Docetaxel
Ibrutinib
Everolimus
Paclitaxel
Cetuximab
|
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors |
Recruiting |
NCT02470585
|
Phase III |
Carboplatin
Paclitaxel
Veliparib
|
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT03734029
|
Phase III |
DS-8201a
nab-paclitaxel
Capecitabine
Paclitaxel
Gemcitabine
Eribulin
|
DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] |
Recruiting |
NCT02419495
|
Phase I |
Cyclophosphamide
Pemetrexed
Eribulin
Selinexor
Carboplatin
Paclitaxel
Topotecan
Dexamethasone
Doxorubicin
|
Selinexor in Combination With Standard Chemotherapy |
Recruiting |
NCT02576574
|
Phase III |
Gemcitabine
Paclitaxel
Cisplatin
Avelumab
Pemetrexed
Carboplatin
|
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) |
Active, not recruiting |
NCT01820754
|
Phase II |
Cisplatin
Ipilimumab
Carboplatin
Paclitaxel
|
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) |
Completed |
NCT02725268
|
Phase II |
Paclitaxel
Sapanisertib
MLN1117 + Sapanisertib
|
Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer |
Active, not recruiting |
NCT02502266
|
Phase II |
Topotecan
Paclitaxel
Doxorubicin
Olaparib
Cediranib
|
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recruiting |
NCT01982448
|
Phase II |
Paclitaxel
Cisplatin
|
Cisplatin vs Paclitaxel for Triple Neg |
Active, not recruiting |
NCT01653470
|
Phase I |
Carboplatin
FOLFIRI
BMS-906024
Paclitaxel
|
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors |
Completed |
NCT02302807
|
Phase III |
Paclitaxel
Vinorelbine
Atezolizumab
Docetaxel
|
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer |
Completed |
NCT02366949
|
Phase I |
BAY1217389 + Paclitaxel
Paclitaxel
|
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
Active, not recruiting |
NCT02117024
|
Phase II |
HS-110 + Cyclophosphamide
Pemetrexed
Vinorelbine
Erlotinib
Gemcitabine
Docetaxel
Paclitaxel
|
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT02929576
|
Phase III |
Paclitaxel
Enzalutamide + Paclitaxel
Enzalutamide
|
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) |
Withdrawn |
NCT02390427
|
Phase I |
Trastuzumab
Paclitaxel
Pertuzumab
Taselisib
|
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer |
Recruiting |
NCT01187199
|
Phase I |
Bevacizumab
Paclitaxel
Carboplatin
Sorafenib
Temsirolimus
|
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
Active, not recruiting |
NCT01897441
|
Phase I |
Paclitaxel
Trastuzumab + Paclitaxel
Doxorubicin + Cyclophosphamide
|
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer |
Recruiting |
NCT01215136
|
Phase II |
Everolimus
Paclitaxel
|
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma |
Active, not recruiting |
NCT02446600
|
Phase III |
Paclitaxel
Doxorubicin
Gemcitabine
Carboplatin
Olaparib
Cediranib
|
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT02389751
|
Phase I |
Carboplatin
Paclitaxel
Ganetespib
|
A Study of Ganetespib in Combination With Chemoradiation |
Active, not recruiting |
NCT01493505
|
Phase III |
Carboplatin
Paclitaxel
Trebananib
|
TRINOVA-3 |
Terminated |
NCT02162719
|
Phase II |
Ipatasertib + Paclitaxel
Paclitaxel
|
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer |
Active, not recruiting |
NCT02412722
|
Phase I |
Sapanisertib
Paclitaxel
|
Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies |
Completed |
NCT01454102
|
Phase I |
Bevacizumab
Ipilimumab
Cisplatin
Pemetrexed
Gemcitabine
Erlotinib
Carboplatin
Paclitaxel
Nivolumab
|
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) |
Active, not recruiting |
NCT02651610
|
Phase II |
Bavituximab
Paclitaxel
|
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer |
Withdrawn |
NCT02264990
|
Phase III |
Pemetrexed
Carboplatin
Paclitaxel
Veliparib
Cisplatin
|
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers |
Active, not recruiting |
NCT00993655
|
Phase III |
Cisplatin
Paclitaxel
Carboplatin
|
Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
Completed |
NCT02437812
|
Phase II |
Paclitaxel
Carboplatin
Metformin
|
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma |
Recruiting |
NCT03770299
|
Phase II |
Docetaxel
Nivolumab
Paclitaxel
Cisplatin
Carboplatin
Gemcitabine
Pemetrexed
Vinorelbine
|
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) |
Not yet recruiting |
NCT03125902
|
Phase III |
Paclitaxel
Atezolizumab + Paclitaxel
|
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) |
Recruiting |
NCT02367794
|
Phase III |
Carboplatin
nab-paclitaxel
Paclitaxel
Atezolizumab
|
A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
NCT01792050
|
Phase II |
Docetaxel
indoximod
Paclitaxel
|
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer |
Unknown status |
NCT02551055
|
Phase I |
Docetaxel
Paclitaxel
Alisertib
TAK-659
MLN1117
|
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma |
Terminated |
NCT01362374
|
Phase I |
Enzalutamide
Paclitaxel
Docetaxel
Ipatasertib
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
|
Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors |
Active, not recruiting |
NCT02322814
|
Phase II |
Paclitaxel
Cobimetinib
|
A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer |
Active, not recruiting |
NCT00989651
|
Phase I |
Bevacizumab + Veliparib
Carboplatin
Paclitaxel
Cisplatin
|
Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT01357161
|
Phase II |
Carboplatin
Adavosertib
Paclitaxel
|
A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) |
Completed |
NCT01236547
|
Phase II |
Paclitaxel
Pazopanib
|
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer |
Active, not recruiting |
NCT03430843
|
Phase III |
Docetaxel
Paclitaxel
BGB-A317
Irinotecan
|
A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma |
Recruiting |
NCT02194829
|
Phase Ib/II |
Paclitaxel
Gemcitabine
Adavosertib
|
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery |
Active, not recruiting |